Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Pulse Biosciences CS
(NQ:
PLSE
)
18.00
+0.96 (+5.60%)
Streaming Delayed Price
Updated: 3:26 PM EDT, Oct 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Pulse Biosciences CS
< Previous
1
2
3
4
5
Next >
Pulse Biosciences Schedules Third Quarter 2024 Financial Results Conference Call for October 30, 2024
October 21, 2024
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Reports Business Updates and Preliminary Second Quarter 2024 Financial Results
August 12, 2024
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors
August 12, 2024
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System
August 08, 2024
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences
August 01, 2024
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Schedules Second Quarter 2024 Financial Results Conference Call for August 12, 2024
July 29, 2024
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX® nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation
July 08, 2024
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences, Inc. Announces the Closing of its Rights Offering
July 03, 2024
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering
June 28, 2024
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000
May 20, 2024
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences’ CellFX Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm Society 2024 Annual Meeting
May 16, 2024
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Enhances Executive Leadership Team
May 14, 2024
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System
May 09, 2024
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Reports Business Updates and First Quarter 2024 Financial Results
May 07, 2024
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000
May 02, 2024
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024
April 24, 2024
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results
March 28, 2024
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Announces Plans to Initiate a Rights Offering
March 28, 2024
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024
March 14, 2024
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System
March 08, 2024
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study
February 14, 2024
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium
January 31, 2024
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac Clamp
January 02, 2024
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX™ Nanosecond Pulsed Field Ablation (nsPFA™) Cardiac Catheter
December 20, 2023
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX nsPFA Percutaneous Electrode
November 21, 2023
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference
November 15, 2023
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Reports Business Updates and Third Quarter 2023 Financial Results
November 13, 2023
From
Pulse Biosciences, Inc.
Via
Business Wire
UPDATE Pulse Biosciences Announces New Time for Third Quarter 2023 Financial Results Conference Call
November 10, 2023
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Schedules Third Quarter 2023 Financial Results Conference Call for November 13, 2023
October 30, 2023
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Appoints Dr. Niv Ad as Chief Science Officer, Cardiac Surgery
October 24, 2023
From
Pulse Biosciences, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.